Matsumoto S, Washizuka Y, Matsumoto Y, Tawara S, Ikeda F, Yokota Y, Karita M
Division of Chemotherapy, New Drug Research Laboratories, Fujisawa Pharmaceutical Co., Ltd, Osaka, Japan.
Antimicrob Agents Chemother. 1997 Dec;41(12):2602-5. doi: 10.1128/AAC.41.12.2602.
We tested whether antibiotic-resistant strains appeared in vivo after the failure of treatment using the Helicobacter pylori-infected euthymic mouse model. The numbers of colonies isolated from 56 ICR mice 2 weeks after 4 days of treatment with metronidazole (3.2, 10, or 32 mg/kg of body weight) or amoxicillin (1, 3.2 or 10 mg/kg), with treatment started 4 days after H. pylori CPY2052 inoculation, were counted, and the isolated strains were tested for their sensitivities to two antibiotics to rule out the presence of antibiotic-resistant strains. One metronidazole-resistant strain was detected in a mouse treated with 10 mg of metronidazole per kg, and the MIC of metronidazole for this strain was 25 microg/ml, compared to a MIC of 1.56 microg/ml for the original strain. However, no resistant strain was detected in the amoxicillin treatment group. After the examination described above, mice challenged with a metronidazole-resistant or -sensitive strain isolated from the stomach of a mouse were treated with metronidazole or amoxicillin. The metronidazole-resistant strain was more difficult to eradicate in vivo than the sensitive strain after treatment with metronidazole but not after treatment with amoxicillin. Thus, a metronidazole-resistant H. pylori strain was selected by insufficient treatment, but no resistant strain was selected with amoxicillin. Eradication of a metronidazole-resistant H. pylori strain in vivo required a higher dosage than eradication of a metronidazole-sensitive H. pylori strain. These results may explain one of the reasons for H. pylori treatment failure.
我们使用幽门螺杆菌感染的正常小鼠模型,测试了治疗失败后体内是否会出现抗生素耐药菌株。在用甲硝唑(3.2、10或32毫克/千克体重)或阿莫西林(1、3.2或10毫克/千克)治疗4天后,于幽门螺杆菌CPY2052接种4天后开始治疗,从56只ICR小鼠中分离出的菌落数量进行了计数,并对分离出的菌株进行了两种抗生素敏感性测试,以排除抗生素耐药菌株的存在。在每千克用10毫克甲硝唑治疗的一只小鼠中检测到一株甲硝唑耐药菌株,该菌株对甲硝唑的最低抑菌浓度(MIC)为25微克/毫升,而原始菌株的MIC为1.56微克/毫升。然而,在阿莫西林治疗组中未检测到耐药菌株。经过上述检查后,用从一只小鼠胃中分离出的甲硝唑耐药或敏感菌株攻击小鼠,然后用甲硝唑或阿莫西林进行治疗。在用甲硝唑治疗后,甲硝唑耐药菌株在体内比敏感菌株更难根除,但在用阿莫西林治疗后并非如此。因此,治疗不足会选择出甲硝唑耐药的幽门螺杆菌菌株,但用阿莫西林不会选择出耐药菌株。在体内根除甲硝唑耐药的幽门螺杆菌菌株所需的剂量高于根除甲硝唑敏感的幽门螺杆菌菌株。这些结果可能解释了幽门螺杆菌治疗失败的原因之一。